Jaguar Health, Inc. (JAGX) 10-Year Financial Performance & Capital Metrics

JAGX • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutJaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.Show more

Revenue $12M +19.8%
EBITDA -$28M +14.1%
Net Income -$38M +6.8%
EPS (Diluted) -130.69 +95.1%
Gross Margin 83.27% +5.2%
EBITDA Margin -243.59% +28.2%
Operating Margin -263.76% +24.9%
Net Margin -329.3% +22.2%
ROE -675.83% +71.0%
ROIC -65.56% +19.0%
Debt/Equity 5.62 -25.7%
Interest Coverage -133.47 -2384.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 15.1%
✓Trading at only 0.0x book value

✗Weaknesses

✗High debt to equity ratio of 5.6x
✗Negative free cash flow
✗Weak momentum: RS Rating 2 (bottom 2%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y15.14%

3Y39.19%

TTM12.45%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-6.76%

EPS CAGR

10Y-

5Y-

3Y-

TTM98.87%

ROCE

10Y Avg-168.47%

5Y Avg-113.22%

3Y Avg-113.36%

Latest-87.47%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	258.38K	141.52K	4.36M	4.42M	5.78M	9.38M	4.33M	11.96M	9.76M	11.69M
Revenue Growth %	-	-0.45%	29.82%	0.01%	0.31%	0.63%	-0.54%	1.76%	-0.18%	0.2%
Cost of Goods Sold+	123.46K	51.97K	880.4K	2.77M	3.82M	3.28M	2.33M	2.02M	2.04M	1.96M
COGS % of Revenue	0.48%	0.37%	0.2%	0.63%	0.66%	0.35%	0.54%	0.17%	0.21%	0.17%
Gross Profit+	134.92K	89.56K	3.48M	1.65M	1.96M	6.11M	2M	9.94M	7.72M	9.73M
Gross Margin %	0.52%	0.63%	0.8%	0.37%	0.34%	0.65%	0.46%	0.83%	0.79%	0.83%
Gross Profit Growth %	-	-0.34%	37.87%	-0.53%	0.19%	2.12%	-0.67%	3.96%	-0.22%	0.26%
Operating Expenses+	12.58M	13.68M	18.6M	27.26M	30.91M	32.75M	42.71M	44.35M	42.02M	40.56M
OpEx % of Revenue	48.69%	96.63%	4.27%	6.17%	5.35%	3.49%	9.85%	3.71%	4.3%	3.47%
Selling, General & Admin	6.1M	6.47M	14.33M	22.11M	20.44M	21M	26M	26.7M	23.05M	24.02M
SG&A % of Revenue	23.63%	45.71%	3.29%	5.01%	3.54%	2.24%	6%	2.23%	2.36%	2.06%
Research & Development	6.48M	7.21M	4.27M	5.15M	5.82M	6.41M	15.08M	17.65M	18.6M	16.54M
R&D % of Revenue	25.06%	50.92%	0.98%	1.17%	1.01%	0.68%	3.48%	1.48%	1.91%	1.42%
Other Operating Expenses	-27.28K	-11.05K	88.55K	0	4.65M	5.34M	1.63M	0	371K	0
Operating Income+	-12.45M	-13.59M	-34.25M	-30.82M	-28.95M	-26.65M	-40.71M	-34.41M	-34.29M	-30.83M
Operating Margin %	-48.17%	-96%	-7.85%	-6.98%	-5.01%	-2.84%	-9.39%	-2.88%	-3.51%	-2.64%
Operating Income Growth %	-0.5%	-0.09%	-1.52%	0.1%	0.06%	0.08%	-0.53%	0.15%	0%	0.1%
EBITDA+	-12.44M	-13.54M	-33.66M	-29.08M	-27.02M	-24.37M	-38.9M	-32.12M	-33.13M	-28.47M
EBITDA Margin %	-48.15%	-95.66%	-7.72%	-6.58%	-4.68%	-2.6%	-8.97%	-2.69%	-3.39%	-2.44%
EBITDA Growth %	-0.49%	-0.09%	-1.49%	0.14%	0.07%	0.1%	-0.6%	0.17%	-0.03%	0.14%
D&A (Non-Cash Add-back)	5.16K	47.49K	584.34K	1.75M	1.93M	2.28M	1.81M	2.29M	1.16M	2.36M
EBIT	-12.97M	-13.59M	-15.12M	-29.52M	-32.8M	-31.02M	-44.18M	-35.67M	-33.92M	-39.02M
Net Interest Income+	-3.32M	-985.55K	-1.21M	-2.63M	-5.73M	-8.13M	-10.05M	-12.72M	-6.38M	-231K
Interest Income	0	0	0	0	0	2.79M	8.42M	0	0	0
Interest Expense	3.32M	985.55K	1.21M	2.63M	5.73M	2.79M	8.42M	12.72M	6.38M	231K
Other Income/Expense	-3.85M	-1.15M	-902.8K	-1.32M	-9.58M	-7.16M	-11.89M	-13.98M	-7.61M	-8.42M
Pretax Income+	-16.29M	-14.73M	-35.15M	-32.15M	-38.53M	-33.81M	-52.6M	-48.4M	-41.9M	-39.25M
Pretax Margin %	-63.05%	-104.11%	-8.06%	-7.28%	-6.67%	-3.6%	-12.13%	-4.05%	-4.29%	-3.36%
Income Tax+	0	0	-13.18M	0	10K	0	0	0	0	0
Effective Tax Rate %	1%	1%	0.62%	1%	1%	1%	1%	0.98%	0.99%	0.98%
Net Income+	-16.29M	-14.73M	-21.97M	-32.15M	-38.54M	-33.81M	-52.59M	-47.45M	-41.3M	-38.49M
Net Margin %	-63.05%	-104.11%	-5.04%	-7.28%	-6.67%	-3.6%	-12.13%	-3.97%	-4.23%	-3.29%
Net Income Growth %	-0.89%	0.1%	-0.49%	-0.46%	-0.2%	0.12%	-0.56%	0.1%	0.13%	0.07%
Net Income (Continuing)	-16.29M	-14.73M	-21.97M	-32.15M	-38.54M	-33.81M	-52.6M	-48.4M	-41.9M	-39.25M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	242K	-699K	-64K	-791K
EPS (Diluted)+	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-2685.00	-130.69
EPS Growth %	-1.34%	0.48%	0.89%	0.96%	1%	0.88%	0.84%	0.64%	1%	0.95%
EPS (Basic)	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-2685.00	-130.69
Diluted Shares Outstanding	0	0	0	0	0	1	5	12	15.42K	294.53K
Basic Shares Outstanding	0	0	0	0	0	1	5	12	15.42K	294.53K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	8.45M	2.56M	3.8M	8.15M	9.52M	17.79M	28.43M	22.32M	27.96M	32.2M
Cash & Short-Term Investments	7.7M	950.98K	520.7K	2.57M	3.5M	8.09M	17.05M	5.47M	6.47M	8M
Cash Only	7.7M	950.98K	520.7K	2.57M	3.5M	8.09M	17.05M	5.47M	6.47M	8M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	59.07K	304.61K	469.04K	1M	1.69M	4.56M	2.14M	2.47M	2.18M	1.65M
Days Sales Outstanding	83.44	785.62	39.26	82.8	107.07	177.35	180.52	75.31	81.67	51.43
Inventory	229.87K	412.75K	2.07M	3.34M	2.13M	2.78M	4.9M	7.02M	9.19M	10.35M
Days Inventory Outstanding	679.61	2.9K	859.35	441.07	203.64	309.58	766.61	1.27K	1.65K	1.93K
Other Current Assets	143.23K	584K	239.17K	6.12K	941K	0	0	7.36M	10.12M	12.2M
Total Non-Current Assets+	3.95M	1.01M	39.83M	32.89M	26.89M	25.05M	24.83M	25.13M	22.8M	21.23M
Property, Plant & Equipment	829.23K	885.95K	1.22M	760.62K	710K	677K	1.73M	1.7M	1.67M	1.4M
Fixed Asset Turnover	0.31x	0.16x	3.57x	5.81x	8.13x	13.86x	2.50x	7.05x	5.84x	8.35x
Goodwill	0	0	5.21M	0	0	0	0	0	0	0
Intangible Assets	0	0	33.4M	31.71M	26.02M	24.34M	22.65M	22.44M	20.12M	18.48M
Long-Term Investments	3M	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	122.16K	122.16K	0	420.83K	154K	37K	446K	995K	1.01M	1.35M
Total Assets+	12.41M	3.56M	43.63M	41.04M	36.41M	42.84M	53.27M	47.45M	50.76M	53.42M
Asset Turnover	0.02x	0.04x	0.10x	0.11x	0.16x	0.22x	0.08x	0.25x	0.19x	0.22x
Asset Growth %	1.15%	-0.71%	11.24%	-0.06%	-0.11%	0.18%	0.24%	-0.11%	0.07%	0.05%
Total Current Liabilities+	3.91M	4.19M	15.39M	26.66M	15.39M	13.22M	15.47M	30.34M	13.99M	19.7M
Accounts Payable	574.46K	517K	7.35M	5.41M	5.35M	4.76M	4.93M	5.81M	4.97M	5.29M
Days Payables Outstanding	1.7K	3.63K	3.05K	714.53	511.92	529.58	771.15	1.05K	891.27	986.9
Short-Term Debt	1.86M	2.07M	5.42M	16.08M	6.78M	3.79M	3.18M	15.88M	4.87M	12.04M
Deferred Revenue (Current)	251.94K	224.45K	177.39K	1000K	0	0	0	0	0	170K
Other Current Liabilities	468.7K	1.16M	2.17M	373.83K	3K	179K	1K	0	0	0
Current Ratio	2.16x	0.61x	0.25x	0.31x	0.62x	1.35x	1.84x	0.74x	2.00x	1.63x
Quick Ratio	2.10x	0.51x	0.11x	0.18x	0.48x	1.14x	1.52x	0.50x	1.34x	1.11x
Cash Conversion Cycle	-935.34	53.41	-2.15K	-190.66	-201.21	-42.65	175.98	295.15	836.93	995.95
Total Non-Current Liabilities+	4.1M	1.82M	10.98M	9M	10.35M	12.42M	25.94M	18.47M	31.88M	27.23M
Long-Term Debt	4.1M	1.82M	10.98M	0	450K	12.42M	25.02M	17.74M	30.99M	23.5M
Capital Lease Obligations	0	0	0	0	0	0	919K	725K	886K	686K
Deferred Tax Liabilities	-3.32K	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	3.32K	6.96K	0	0	9.89M	0	0	0	0	2.48M
Total Liabilities	8.01M	6.02M	26.37M	35.66M	25.74M	25.64M	41.41M	48.81M	45.87M	46.93M
Total Debt+	5.95M	3.89M	16.41M	16.08M	7.57M	16.21M	29.36M	34.84M	37.09M	36.53M
Net Debt	-1.74M	2.94M	15.88M	13.52M	4.07M	8.12M	12.31M	29.37M	30.63M	28.52M
Debt / Equity	1.35x	-	0.95x	2.99x	0.71x	0.94x	2.48x	-	7.57x	5.62x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-3.75x	-13.79x	-28.31x	-11.73x	-5.05x	-9.54x	-4.83x	-2.70x	-5.37x	-133.47x
Total Equity+	4.4M	-2.45M	17.26M	5.38M	10.67M	17.2M	11.85M	-1.36M	4.9M	6.49M
Equity Growth %	3.01%	-1.56%	8.03%	-0.69%	0.98%	0.61%	-0.31%	-1.11%	4.61%	0.33%
Book Value per Share	999999.00	-999999.00	999999.00	999999.00	999999.00	999999.00	999999.00	-115963.51	317.55	22.05
Total Shareholders' Equity	4.4M	-2.45M	17.26M	5.38M	10.67M	17.2M	11.61M	-657K	4.96M	7.29M
Common Stock	812	1.4K	10.53K	6.49K	5K	4K	0	0	0	0
Retained Earnings	-25.7M	-40.44M	-62.4M	-94.55M	-133.09M	-166.9M	-219.49M	-266.95M	-308.25M	-346.48M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-12.41B	-3.56T	-43.63T	-9T	0	0	0	-680K	-652K	-467K
Minority Interest	0	0	0	0	0	0	242K	-699K	-64K	-791K

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-14.32M	-14.41M	-9.82M	-22.73M	-20.46M	-15.28M	-34.97M	-33.1M	-33.24M	-29.38M
Operating CF Margin %	-55.41%	-101.85%	-2.25%	-5.15%	-3.54%	-1.63%	-8.07%	-2.77%	-3.41%	-2.51%
Operating CF Growth %	-1.62%	-0.01%	0.32%	-1.31%	0.1%	0.25%	-1.29%	0.05%	-0%	0.12%
Net Income	-16.29M	-14.73M	-21.97M	-32.15M	-38.54M	-33.81M	-52.6M	-49.08M	-41.87M	-39.03M
Depreciation & Amortization	5.16K	47.49K	584.34K	1.32M	1.93M	2.28M	1.81M	2.29M	2.39M	2.36M
Stock-Based Compensation	992.16K	717.93K	814.61K	2.02M	2.99M	2.82M	3.97M	3.32M	2.11M	1.64M
Deferred Taxes	536.17K	151.2K	-13.18M	5.75M	0	0	4.39M	0	0	0
Other Non-Cash Items	2.73M	549.28K	19.8M	1.25M	13.83M	16.89M	5.19M	14.79M	15.23M	8.66M
Working Capital Changes	-2.28M	-1.15M	4.13M	-925.1K	-662K	-3.47M	2.27M	-4.43M	-11.1M	-3.01M
Change in Receivables	-55.87K	50.9K	-166.06K	-528.02K	-704K	-2.87M	2.82M	-170K	298K	526K
Change in Inventory	-31.84K	-182.88K	128K	-1.27M	1.21M	-653K	-2.12M	-2.12M	-2.17M	-1.16M
Change in Payables	-240.09K	-28.34K	4.19M	-1.94M	-63K	-743K	158K	902K	-855K	328K
Cash from Investing+	-3M	2.38M	-1.29M	-6.53K	0	-7K	-6K	-1.68M	0	-231K
Capital Expenditures	-23.3K	-104.21K	0	-6.53K	0	-7K	-6K	-77K	0	-16K
CapEx % of Revenue	0.09%	0.74%	-	0%	-	0%	0%	0.01%	-	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-2.98M	2.49M	272.13K	-6.53B	0	0	-247K	-1.6M	0	-215K
Cash from Financing+	24.17M	5.28M	10.68M	24.55M	21.77M	19.49M	43.94M	23.18M	34.23M	31.2M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-405.13K	-1.06M	0	-2.12M	9.23M	11.86M	1.31M	-1.16M	1.62M	-608K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-14.34M	-14.52M	-9.82M	-22.74M	-20.46M	-15.29M	-34.98M	-34.78M	-33.24M	-29.61M
FCF Margin %	-55.5%	-102.58%	-2.25%	-5.15%	-3.54%	-1.63%	-8.07%	-2.91%	-3.41%	-2.53%
FCF Growth %	-1.6%	-0.01%	0.32%	-1.31%	0.1%	0.25%	-1.29%	0.01%	0.04%	0.11%
FCF per Share	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-2155.63	-100.55
FCF Conversion (FCF/Net Income)	0.88x	0.98x	0.45x	0.71x	0.53x	0.45x	0.66x	0.70x	0.80x	0.76x
Interest Paid	0	0	0	0	142K	757K	0	0	35K	14K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-592.92%	-1515.11%	-296.74%	-283.92%	-480.05%	-242.58%	-362.04%	-904.14%	-2332.67%	-675.83%
Return on Invested Capital (ROIC)	-782.98%	-649.73%	-152.76%	-88.84%	-129.07%	-99.76%	-123.38%	-98.94%	-80.96%	-65.56%
Gross Margin	52.22%	63.28%	79.81%	37.37%	33.92%	65.05%	46.18%	83.11%	79.13%	83.27%
Net Margin	-6305.24%	-10410.87%	-503.73%	-727.92%	-667.34%	-360.25%	-1213.26%	-396.91%	-423.11%	-329.3%
Debt / Equity	1.35x	-	0.95x	2.99x	0.71x	0.94x	2.48x	-	7.57x	5.62x
Interest Coverage	-3.75x	-13.79x	-28.31x	-11.73x	-5.05x	-9.54x	-4.83x	-2.70x	-5.37x	-133.47x
FCF Conversion	0.88x	0.98x	0.45x	0.71x	0.53x	0.45x	0.66x	0.70x	0.80x	0.76x
Revenue Growth	-	-45.23%	2981.61%	1.26%	30.77%	62.51%	-53.81%	175.8%	-18.36%	19.75%

Revenue by Segment

	2017	2018	2019	2020	2021	2022	2023	2024
Mytesi	1.06M	4.12M	5.67M	9.3M	3.3M	11.7M	9.6M	11.3M
Mytesi Growth	-	287.79%	37.63%	63.93%	-64.52%	254.55%	-17.95%	17.71%
License	-	-	-	-	-	-	-	129K
License Growth	-	-	-	-	-	-	-	-
Neonorm	344.19K	116.84K	102.19K	76K	62K	48K	42K	28K
Neonorm Growth	-	-66.05%	-12.54%	-25.63%	-18.42%	-22.58%	-12.50%	-33.33%
Botanical Extract	78K	-	-	-	-	-	-	-
Botanical Extract Growth	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Jaguar Health, Inc. (JAGX) reported $11.8M in revenue for fiscal year 2024.

Jaguar Health, Inc. (JAGX) grew revenue by 19.8% over the past year. This is strong growth.

Jaguar Health, Inc. (JAGX) reported a net loss of $40.3M for fiscal year 2024.

Dividend & Returns

Jaguar Health, Inc. (JAGX) has a return on equity (ROE) of -675.8%. Negative ROE indicates the company is unprofitable.

Jaguar Health, Inc. (JAGX) had negative free cash flow of $26.1M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Jaguar Health, Inc. (JAGX) 10-Year Financial Performance & Capital Metrics

JAGX • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $12M +19.8%
EBITDA -$28M +14.1%
Net Income -$38M +6.8%
EPS (Diluted) -130.69 +95.1%
Gross Margin 83.27% +5.2%
EBITDA Margin -243.59% +28.2%
Operating Margin -263.76% +24.9%
Net Margin -329.3% +22.2%
ROE -675.83% +71.0%
ROIC -65.56% +19.0%
Debt/Equity 5.62 -25.7%
Interest Coverage -133.47 -2384.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 15.1%
✓Trading at only 0.0x book value

✗Weaknesses

✗High debt to equity ratio of 5.6x
✗Negative free cash flow
✗Weak momentum: RS Rating 2 (bottom 2%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y15.14%

3Y39.19%

TTM12.45%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-6.76%

EPS CAGR

10Y-

5Y-

3Y-

TTM98.87%

ROCE

10Y Avg-168.47%

5Y Avg-113.22%

3Y Avg-113.36%

Latest-87.47%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	258.38K	141.52K	4.36M	4.42M	5.78M	9.38M	4.33M	11.96M	9.76M	11.69M
Revenue Growth %	-	-0.45%	29.82%	0.01%	0.31%	0.63%	-0.54%	1.76%	-0.18%	0.2%
Cost of Goods Sold+	123.46K	51.97K	880.4K	2.77M	3.82M	3.28M	2.33M	2.02M	2.04M	1.96M
COGS % of Revenue	0.48%	0.37%	0.2%	0.63%	0.66%	0.35%	0.54%	0.17%	0.21%	0.17%
Gross Profit+	134.92K	89.56K	3.48M	1.65M	1.96M	6.11M	2M	9.94M	7.72M	9.73M
Gross Margin %	0.52%	0.63%	0.8%	0.37%	0.34%	0.65%	0.46%	0.83%	0.79%	0.83%
Gross Profit Growth %	-	-0.34%	37.87%	-0.53%	0.19%	2.12%	-0.67%	3.96%	-0.22%	0.26%
Operating Expenses+	12.58M	13.68M	18.6M	27.26M	30.91M	32.75M	42.71M	44.35M	42.02M	40.56M
OpEx % of Revenue	48.69%	96.63%	4.27%	6.17%	5.35%	3.49%	9.85%	3.71%	4.3%	3.47%
Selling, General & Admin	6.1M	6.47M	14.33M	22.11M	20.44M	21M	26M	26.7M	23.05M	24.02M
SG&A % of Revenue	23.63%	45.71%	3.29%	5.01%	3.54%	2.24%	6%	2.23%	2.36%	2.06%
Research & Development	6.48M	7.21M	4.27M	5.15M	5.82M	6.41M	15.08M	17.65M	18.6M	16.54M
R&D % of Revenue	25.06%	50.92%	0.98%	1.17%	1.01%	0.68%	3.48%	1.48%	1.91%	1.42%
Other Operating Expenses	-27.28K	-11.05K	88.55K	0	4.65M	5.34M	1.63M	0	371K	0
Operating Income+	-12.45M	-13.59M	-34.25M	-30.82M	-28.95M	-26.65M	-40.71M	-34.41M	-34.29M	-30.83M
Operating Margin %	-48.17%	-96%	-7.85%	-6.98%	-5.01%	-2.84%	-9.39%	-2.88%	-3.51%	-2.64%
Operating Income Growth %	-0.5%	-0.09%	-1.52%	0.1%	0.06%	0.08%	-0.53%	0.15%	0%	0.1%
EBITDA+	-12.44M	-13.54M	-33.66M	-29.08M	-27.02M	-24.37M	-38.9M	-32.12M	-33.13M	-28.47M
EBITDA Margin %	-48.15%	-95.66%	-7.72%	-6.58%	-4.68%	-2.6%	-8.97%	-2.69%	-3.39%	-2.44%
EBITDA Growth %	-0.49%	-0.09%	-1.49%	0.14%	0.07%	0.1%	-0.6%	0.17%	-0.03%	0.14%
D&A (Non-Cash Add-back)	5.16K	47.49K	584.34K	1.75M	1.93M	2.28M	1.81M	2.29M	1.16M	2.36M
EBIT	-12.97M	-13.59M	-15.12M	-29.52M	-32.8M	-31.02M	-44.18M	-35.67M	-33.92M	-39.02M
Net Interest Income+	-3.32M	-985.55K	-1.21M	-2.63M	-5.73M	-8.13M	-10.05M	-12.72M	-6.38M	-231K
Interest Income	0	0	0	0	0	2.79M	8.42M	0	0	0
Interest Expense	3.32M	985.55K	1.21M	2.63M	5.73M	2.79M	8.42M	12.72M	6.38M	231K
Other Income/Expense	-3.85M	-1.15M	-902.8K	-1.32M	-9.58M	-7.16M	-11.89M	-13.98M	-7.61M	-8.42M
Pretax Income+	-16.29M	-14.73M	-35.15M	-32.15M	-38.53M	-33.81M	-52.6M	-48.4M	-41.9M	-39.25M
Pretax Margin %	-63.05%	-104.11%	-8.06%	-7.28%	-6.67%	-3.6%	-12.13%	-4.05%	-4.29%	-3.36%
Income Tax+	0	0	-13.18M	0	10K	0	0	0	0	0
Effective Tax Rate %	1%	1%	0.62%	1%	1%	1%	1%	0.98%	0.99%	0.98%
Net Income+	-16.29M	-14.73M	-21.97M	-32.15M	-38.54M	-33.81M	-52.59M	-47.45M	-41.3M	-38.49M
Net Margin %	-63.05%	-104.11%	-5.04%	-7.28%	-6.67%	-3.6%	-12.13%	-3.97%	-4.23%	-3.29%
Net Income Growth %	-0.89%	0.1%	-0.49%	-0.46%	-0.2%	0.12%	-0.56%	0.1%	0.13%	0.07%
Net Income (Continuing)	-16.29M	-14.73M	-21.97M	-32.15M	-38.54M	-33.81M	-52.6M	-48.4M	-41.9M	-39.25M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	242K	-699K	-64K	-791K
EPS (Diluted)+	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-2685.00	-130.69
EPS Growth %	-1.34%	0.48%	0.89%	0.96%	1%	0.88%	0.84%	0.64%	1%	0.95%
EPS (Basic)	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-2685.00	-130.69
Diluted Shares Outstanding	0	0	0	0	0	1	5	12	15.42K	294.53K
Basic Shares Outstanding	0	0	0	0	0	1	5	12	15.42K	294.53K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	8.45M	2.56M	3.8M	8.15M	9.52M	17.79M	28.43M	22.32M	27.96M	32.2M
Cash & Short-Term Investments	7.7M	950.98K	520.7K	2.57M	3.5M	8.09M	17.05M	5.47M	6.47M	8M
Cash Only	7.7M	950.98K	520.7K	2.57M	3.5M	8.09M	17.05M	5.47M	6.47M	8M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	59.07K	304.61K	469.04K	1M	1.69M	4.56M	2.14M	2.47M	2.18M	1.65M
Days Sales Outstanding	83.44	785.62	39.26	82.8	107.07	177.35	180.52	75.31	81.67	51.43
Inventory	229.87K	412.75K	2.07M	3.34M	2.13M	2.78M	4.9M	7.02M	9.19M	10.35M
Days Inventory Outstanding	679.61	2.9K	859.35	441.07	203.64	309.58	766.61	1.27K	1.65K	1.93K
Other Current Assets	143.23K	584K	239.17K	6.12K	941K	0	0	7.36M	10.12M	12.2M
Total Non-Current Assets+	3.95M	1.01M	39.83M	32.89M	26.89M	25.05M	24.83M	25.13M	22.8M	21.23M
Property, Plant & Equipment	829.23K	885.95K	1.22M	760.62K	710K	677K	1.73M	1.7M	1.67M	1.4M
Fixed Asset Turnover	0.31x	0.16x	3.57x	5.81x	8.13x	13.86x	2.50x	7.05x	5.84x	8.35x
Goodwill	0	0	5.21M	0	0	0	0	0	0	0
Intangible Assets	0	0	33.4M	31.71M	26.02M	24.34M	22.65M	22.44M	20.12M	18.48M
Long-Term Investments	3M	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	122.16K	122.16K	0	420.83K	154K	37K	446K	995K	1.01M	1.35M
Total Assets+	12.41M	3.56M	43.63M	41.04M	36.41M	42.84M	53.27M	47.45M	50.76M	53.42M
Asset Turnover	0.02x	0.04x	0.10x	0.11x	0.16x	0.22x	0.08x	0.25x	0.19x	0.22x
Asset Growth %	1.15%	-0.71%	11.24%	-0.06%	-0.11%	0.18%	0.24%	-0.11%	0.07%	0.05%
Total Current Liabilities+	3.91M	4.19M	15.39M	26.66M	15.39M	13.22M	15.47M	30.34M	13.99M	19.7M
Accounts Payable	574.46K	517K	7.35M	5.41M	5.35M	4.76M	4.93M	5.81M	4.97M	5.29M
Days Payables Outstanding	1.7K	3.63K	3.05K	714.53	511.92	529.58	771.15	1.05K	891.27	986.9
Short-Term Debt	1.86M	2.07M	5.42M	16.08M	6.78M	3.79M	3.18M	15.88M	4.87M	12.04M
Deferred Revenue (Current)	251.94K	224.45K	177.39K	1000K	0	0	0	0	0	170K
Other Current Liabilities	468.7K	1.16M	2.17M	373.83K	3K	179K	1K	0	0	0
Current Ratio	2.16x	0.61x	0.25x	0.31x	0.62x	1.35x	1.84x	0.74x	2.00x	1.63x
Quick Ratio	2.10x	0.51x	0.11x	0.18x	0.48x	1.14x	1.52x	0.50x	1.34x	1.11x
Cash Conversion Cycle	-935.34	53.41	-2.15K	-190.66	-201.21	-42.65	175.98	295.15	836.93	995.95
Total Non-Current Liabilities+	4.1M	1.82M	10.98M	9M	10.35M	12.42M	25.94M	18.47M	31.88M	27.23M
Long-Term Debt	4.1M	1.82M	10.98M	0	450K	12.42M	25.02M	17.74M	30.99M	23.5M
Capital Lease Obligations	0	0	0	0	0	0	919K	725K	886K	686K
Deferred Tax Liabilities	-3.32K	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	3.32K	6.96K	0	0	9.89M	0	0	0	0	2.48M
Total Liabilities	8.01M	6.02M	26.37M	35.66M	25.74M	25.64M	41.41M	48.81M	45.87M	46.93M
Total Debt+	5.95M	3.89M	16.41M	16.08M	7.57M	16.21M	29.36M	34.84M	37.09M	36.53M
Net Debt	-1.74M	2.94M	15.88M	13.52M	4.07M	8.12M	12.31M	29.37M	30.63M	28.52M
Debt / Equity	1.35x	-	0.95x	2.99x	0.71x	0.94x	2.48x	-	7.57x	5.62x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-3.75x	-13.79x	-28.31x	-11.73x	-5.05x	-9.54x	-4.83x	-2.70x	-5.37x	-133.47x
Total Equity+	4.4M	-2.45M	17.26M	5.38M	10.67M	17.2M	11.85M	-1.36M	4.9M	6.49M
Equity Growth %	3.01%	-1.56%	8.03%	-0.69%	0.98%	0.61%	-0.31%	-1.11%	4.61%	0.33%
Book Value per Share	999999.00	-999999.00	999999.00	999999.00	999999.00	999999.00	999999.00	-115963.51	317.55	22.05
Total Shareholders' Equity	4.4M	-2.45M	17.26M	5.38M	10.67M	17.2M	11.61M	-657K	4.96M	7.29M
Common Stock	812	1.4K	10.53K	6.49K	5K	4K	0	0	0	0
Retained Earnings	-25.7M	-40.44M	-62.4M	-94.55M	-133.09M	-166.9M	-219.49M	-266.95M	-308.25M	-346.48M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-12.41B	-3.56T	-43.63T	-9T	0	0	0	-680K	-652K	-467K
Minority Interest	0	0	0	0	0	0	242K	-699K	-64K	-791K

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-14.32M	-14.41M	-9.82M	-22.73M	-20.46M	-15.28M	-34.97M	-33.1M	-33.24M	-29.38M
Operating CF Margin %	-55.41%	-101.85%	-2.25%	-5.15%	-3.54%	-1.63%	-8.07%	-2.77%	-3.41%	-2.51%
Operating CF Growth %	-1.62%	-0.01%	0.32%	-1.31%	0.1%	0.25%	-1.29%	0.05%	-0%	0.12%
Net Income	-16.29M	-14.73M	-21.97M	-32.15M	-38.54M	-33.81M	-52.6M	-49.08M	-41.87M	-39.03M
Depreciation & Amortization	5.16K	47.49K	584.34K	1.32M	1.93M	2.28M	1.81M	2.29M	2.39M	2.36M
Stock-Based Compensation	992.16K	717.93K	814.61K	2.02M	2.99M	2.82M	3.97M	3.32M	2.11M	1.64M
Deferred Taxes	536.17K	151.2K	-13.18M	5.75M	0	0	4.39M	0	0	0
Other Non-Cash Items	2.73M	549.28K	19.8M	1.25M	13.83M	16.89M	5.19M	14.79M	15.23M	8.66M
Working Capital Changes	-2.28M	-1.15M	4.13M	-925.1K	-662K	-3.47M	2.27M	-4.43M	-11.1M	-3.01M
Change in Receivables	-55.87K	50.9K	-166.06K	-528.02K	-704K	-2.87M	2.82M	-170K	298K	526K
Change in Inventory	-31.84K	-182.88K	128K	-1.27M	1.21M	-653K	-2.12M	-2.12M	-2.17M	-1.16M
Change in Payables	-240.09K	-28.34K	4.19M	-1.94M	-63K	-743K	158K	902K	-855K	328K
Cash from Investing+	-3M	2.38M	-1.29M	-6.53K	0	-7K	-6K	-1.68M	0	-231K
Capital Expenditures	-23.3K	-104.21K	0	-6.53K	0	-7K	-6K	-77K	0	-16K
CapEx % of Revenue	0.09%	0.74%	-	0%	-	0%	0%	0.01%	-	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-2.98M	2.49M	272.13K	-6.53B	0	0	-247K	-1.6M	0	-215K
Cash from Financing+	24.17M	5.28M	10.68M	24.55M	21.77M	19.49M	43.94M	23.18M	34.23M	31.2M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-405.13K	-1.06M	0	-2.12M	9.23M	11.86M	1.31M	-1.16M	1.62M	-608K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-14.34M	-14.52M	-9.82M	-22.74M	-20.46M	-15.29M	-34.98M	-34.78M	-33.24M	-29.61M
FCF Margin %	-55.5%	-102.58%	-2.25%	-5.15%	-3.54%	-1.63%	-8.07%	-2.91%	-3.41%	-2.53%
FCF Growth %	-1.6%	-0.01%	0.32%	-1.31%	0.1%	0.25%	-1.29%	0.01%	0.04%	0.11%
FCF per Share	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-2155.63	-100.55
FCF Conversion (FCF/Net Income)	0.88x	0.98x	0.45x	0.71x	0.53x	0.45x	0.66x	0.70x	0.80x	0.76x
Interest Paid	0	0	0	0	142K	757K	0	0	35K	14K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-592.92%	-1515.11%	-296.74%	-283.92%	-480.05%	-242.58%	-362.04%	-904.14%	-2332.67%	-675.83%
Return on Invested Capital (ROIC)	-782.98%	-649.73%	-152.76%	-88.84%	-129.07%	-99.76%	-123.38%	-98.94%	-80.96%	-65.56%
Gross Margin	52.22%	63.28%	79.81%	37.37%	33.92%	65.05%	46.18%	83.11%	79.13%	83.27%
Net Margin	-6305.24%	-10410.87%	-503.73%	-727.92%	-667.34%	-360.25%	-1213.26%	-396.91%	-423.11%	-329.3%
Debt / Equity	1.35x	-	0.95x	2.99x	0.71x	0.94x	2.48x	-	7.57x	5.62x
Interest Coverage	-3.75x	-13.79x	-28.31x	-11.73x	-5.05x	-9.54x	-4.83x	-2.70x	-5.37x	-133.47x
FCF Conversion	0.88x	0.98x	0.45x	0.71x	0.53x	0.45x	0.66x	0.70x	0.80x	0.76x
Revenue Growth	-	-45.23%	2981.61%	1.26%	30.77%	62.51%	-53.81%	175.8%	-18.36%	19.75%

Revenue by Segment

	2017	2018	2019	2020	2021	2022	2023	2024
Mytesi	1.06M	4.12M	5.67M	9.3M	3.3M	11.7M	9.6M	11.3M
Mytesi Growth	-	287.79%	37.63%	63.93%	-64.52%	254.55%	-17.95%	17.71%
License	-	-	-	-	-	-	-	129K
License Growth	-	-	-	-	-	-	-	-
Neonorm	344.19K	116.84K	102.19K	76K	62K	48K	42K	28K
Neonorm Growth	-	-66.05%	-12.54%	-25.63%	-18.42%	-22.58%	-12.50%	-33.33%
Botanical Extract	78K	-	-	-	-	-	-	-
Botanical Extract Growth	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Jaguar Health, Inc. (JAGX) reported $11.8M in revenue for fiscal year 2024.

Jaguar Health, Inc. (JAGX) grew revenue by 19.8% over the past year. This is strong growth.

Jaguar Health, Inc. (JAGX) reported a net loss of $40.3M for fiscal year 2024.

Dividend & Returns

Jaguar Health, Inc. (JAGX) has a return on equity (ROE) of -675.8%. Negative ROE indicates the company is unprofitable.

Jaguar Health, Inc. (JAGX) had negative free cash flow of $26.1M in fiscal year 2024, likely due to heavy capital investments.